1. Whitney, CG, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003; 348: 1737–1746.
2. Schuchat, A, et al. for the Active Surveillance Team. Bacterial meningitis in the United States in 1995. New England Journal of Medicine 1997; 337: 970–976.
3. Pollard, AJ, Moxon, ER. The meningococcus tamed? Archives of Disease in Childhood 2002; 87: 13–17.
4. Rosenstein, NE, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. Journal of Infectious Diseases 1999; 180: 1894–1901.
5. American Public Health Association. In: Heymann DL, ed. Control of Communicable Diseases Manual, 18th edn. Washington, 2004, p. 359.
6. Nadel, S, Kroll, JS. Diagnosis and management of meningococcal disease: the need for centralized care. FEMS Microbiology Reviews 2007; 31: 71–83.
7. Rosenstein, NE, et al. Meningococcal disease. New England Journal of Medicine 2001; 344: 1378–1388.
8. Dankert, J. Neisseria. In: Cohen, J, Powderly, WG eds. Infectious Diseases, 2nd edn. Edinburgh: Mosby, 2004, pp. 2173–2186.
9. Lapeyssonnie, L. Cerebrospinal meningitis in Africa [in French]. Bulletin of the WHO 1963; 28 (Suppl.) : 3–114.
10. Wang, JF, et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infection and Immunity 1992; 60: 5267–5282.
11. Tsolia, MN, et al. The evolving epidemiology of invasive meningococcal disease: a two-year prospective, population-based study in children in the area of Athens. FEMS Immunology and Medical Microbiology 2003; 36: 87–94.
12. Block, C, et al. Forty years of meningococcal disease in Israel 1951–1990. Clinical Infectious Disease 1993; 17: 126–132.
13. Williams, CJ, et al. Geographic correlation between deprivation and risk of meningococcal disease: an ecological study. BMC Public Health 2004; 4: 30.
14. Heyderman, RS, et al. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Archives of Disease in Childhood 2004; 89: 1064–1068.
15. Fone, DL, et al. Meningococcal disease and social deprivation: a small area geographical study in Gwent, UK. Epidemiology and Infection 2003; 30: 53–58.
16. Pereiró, I, et al. Risk factors for invasive disease among children in Spain. Journal of Infection 2004; 48: 320–329.
17. Deutch, S, et al. Crowding as a risk factor of meningococcal disease in Danish preschool children: a nationwide population-based case-control study. Scandinavian Journal of Infectious Diseases 2004; 36: 20–23.
18. Centres for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weeekly Report 2005; 54 (No. RR-7): 1–21.
19. Centres for Diseases Control and Prevention. Standardized molecular subtyping of foodborne bacterial pathogens by pulsed-field gel electrophoresis. CDC training manual. Centres for Disease Control and Prevention, Atlanta, GA, 2000.
20. Ministry of Health, Israel. Weekly Epidemiological Reports 1999–2005, Department of Epidemiology, Public Health Services, Ministry of Health, Israel (http://www.health.gov.il).
21. Central Bureau of Statistics. Statistical Abstract of Israel 2005-No.56. Chapter 2. Population. Table 2.7 Localities and population by district, sub-district, area, population group and religion. State of Israel. Central Bureau of Statistics. Jerusalem 2005.
22. Statistical Yearbook of Jerusalem 2005. Choshen M, ed. Chapter III, Population Table III/12 – Population of Jerusalem, by Population Group and Age, 1997–2003. Jerusalem, 2005.
23. Hoebe, CJ, et al. Space-time cluster analysis of invasive meningococcal disease. Emerging Infectious Diseases 2004; 10: 1621–1626.
24. Abramson, JH. WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiologic Perspectives & Innovations 2004; 1: 6.
25. American Academy of Pediatrics. Meningococcal infections. In: Pickering, LK, ed. 2003 Red Book: Report of the Committee on Infectious Diseases, 26th edn. Elk Grove Village, IL. American Academy of Pediatrics, 2003, pp. 430–432.
26. Almog, R, et al. First recorded outbreaks of meningococcal disease in the Israel Defence Force: three clusters due to serogroup C and the emergence of resistance to rifampicin. Infection 1994; 22: 69–71.
27. Shehab, S, et al. Failure of mass antibiotic prophylaxis to control a prolonged outbreak of meningococcal disease in an Israeli village. European Journal of Clinical Microbiology and Infectious Diseases 1998; 17: 749–753.
28. Goldacre, MJ, Roberts, SE, Yeates, D. Case fatality rates for meningococcal disease in an English population, 1963–98: database study. British Medical Journal 2003; 327: 596–597.
29. Sharip, A, et al. Population-based analysis of meningococcal disease mortality in the United States: 1990–2002. Pediatric Infectious Disease Journal 2006; 25: 191–194.
30. Smith, I, et al. Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985–2002. Epidemiology and Infection 2006; 134: 103–110.
31. Jackson, LA, Wenger, JD. Laboratory-Based Surveillance for Meningococcal Disease in Selected Areas, United States, 1989–1991. Morbidity and Mortality Weeekly Report. Surveillance Summaries 1993; 42 (SS-2); 21–30.
32. Purcell, B, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. British Medical Journal 2004; 328: 1339.
33. Ministry of Health Israel. Public Health Services, Department of Epidemiology. In: Immunization Guidelines 1999, Chap. 16. Meningococcal Disease p. 2–7 (Chemoprophylaxis). Jerusalem, Israel, 1999.
34. Davison, KL, et al. Clusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk? Archives of Diseases in Childhood 2004; 89: 256–260.
35. Yazdankhah, SP, Lindstedt, BA, Caugant, DA. Use of variable-number tandem repeats to examine genetic diversity of Neisseria meningitidis. Journal of Clinical Microbiology 2005; 43: 1699–1705.
36. Trotter, C, et al. Ascertainment of meningococcal disease in Europe. Eurosurveillance 2005; 10: 247–250.
37. Holst, J, et al. The concept of ‘tailor-made’, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23: 2202–2205.
38. O'Hallahan, J, et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 2005; 23: 2197–2201.
39. Hall, RG. The control of meningococcal disease. Medical Journal of Australia 2002; 176: 573–574.
40. Perrett, KP, Pollard, AJ. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opinion on Biological Therapy 2005; 5: 1611–1625.
41. Girard, MP, et al. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24: 4692–4700.